Tag: pharmaceuticals
-
Instrument Company to License Scripps Screening Technology
Brooks Life Science Systems, a division of Brooks Automation in Poway, California, and Scripps Research Institute in Jupiter, Florida have agreed for Brooks to commercialize technology developed at Scripps to manage compounds in high-throughput screening, a process for drug discovery. Brooks Automation is a provider of instrumentation technology for manufacturing, energy, and life sciences companies.…
-
FDA Grants Priority Review to Breast Cancer Therapy
Genentech in South San Francisco, California, says the Food and Drug Administration has granted priority review status to its drug pertuzumab to treat human epidermal growth factor receptor 2- (HER2-) positive breast cancer. Genentech is a division of the global pharmaceutical company Roche, headquartered in Switzerland. FDA applies the priority review status in this case…
-
Stem Cell Method Developed to Increase Bone Strength
Medical researchers from University of California at Davis and engineering faculty at University of California at Berkeley have developed a technique to increase bone growth by stimulating stem cell activity in bones. The team’s findings appear online in the journal Nature Medicine (paid subscription required). The research team led by Wei Yao of UC Davis’s…
-
Grants for Orphan Disease Academic-Industry Partnerships
The Wellcome Trust in the U.K. has unveiled new funding for academic-industry partnerships in early-stage research and development projects targeting orphan and neglected diseases. The Pathfinder Awards aim to encourage pilot research projects with potential for developing new products that address diseases affecting a small percentage of the population (orphan diseases) or conditions that that…
-
Merck, Biopharm to Partner on Hypoxia-Targeting Cancer Drug
Threshold Pharmaceuticals Inc., a biopharmaceutical company in South San Francisco, California and Merck KGaA, the global drug manufacturer in Darmstadt, Germany have agreed to co-develop and commercialize Threshold’s drug TH-302. The drug TH-302 targets hypoxia, caused by low oxygen levels due to insufficient blood vessel growth, a common condition of tissues with many solid tumors,…
-
Warfarin, Aspirin Provide Similar Stroke Prevention
In a six-year, 11-country clinical trial, researchers at Columbia University found aspirin and the anti-clotting drug warfarin to offer about equal protection against death and strokes in heart failure patients with normal heart rhythms. The findings of the study led by Columbia medical school professor Shunichi Homma were presented at the International Stroke Conference in…
-
Sanofi to Cut Genzyme Massachusetts Research Staff
The French pharmaceutical maker Sanofi says it will reduce its research workforce employed in and around Boston, as a result of its acquisition of Genzyme Corporation a year ago. Sanofi confirmed the cuts today in a statement to the industry Web site Fierce Biotech. Genzyme, headquartered in Cambridge, Massachusetts, was acquired by Sanofi last year…
-
Prostate Cancer Therapy Shown Effective in Chemo Patients
A phase 3 clinical trial has shown a new drug to treat prostate cancer is effective with patients who had previously been treated with chemotherapy. The results of the study of MDV3100 — made by the biopharmaceutical company Medivation Inc. in San Francisco and Astellas Pharma Inc. in Tokyo, Japan — will be presented tomorrow…
-
Canadian Govt Opens Call for Personalized Medicines R&D
The Canadian government opened a matching grant competition for research proposals on personalized medicine. The call seeks research proposals that can take treatments from “one size fits all” to more precise treatments and interventions addressing specific characteristics of the individual, made possible by new diagnostic technologies that look at patients’ unique genetic signatures. The competition…
-
$600K Foundation Grant to Fund Cancer Genomics Research
The National Foundation for Cancer Research (NFCR) has awarded a $600,000 grant to the Translational Genomics Research Institute (TGen) in Phoenix and the University of Arizona in Tucson for the study of targeted cancer therapies. The three-year grant will enable TGen and the university to continue its NFCR Center for Targeted Cancer Therapies, created in…